Literature DB >> 6140285

Histamine H2-antagonists--past, present and future.

R T Brittain, D Jack.   

Abstract

In this selective review of histamine H2-antagonists, we emphasize the significance of burimamide, the first specific H2-antagonist, in physiology and pharmacology and describe how its discovery led to the development of cimetidine as a new treatment of acid-aggravated disease of the alimentary tract. Developments since cimetidine, include ranitidine, which is a more potent, selectively acting H2-antagonist. A new series of H2-blockers with prolonged activity is discussed, and exemplified, particularly AH 23844. Its prolonged action and its unusual, apparently insurmountable, blocking action is explained in fundamental physicochemical terms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140285     DOI: 10.1097/00004836-198312001-00007

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

1.  JB-9322, a new selective histamine H2-receptor antagonist with potent gastric mucosal protective properties.

Authors:  B Palacios; M J Montero; M A Sevilla; L S Román
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

2.  1976 and all that!--20 years of antisecretory therapy.

Authors:  A Garner; H Fadlallah; M E Parsons
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 3.  Safety by design.

Authors:  D Jack
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.